NCT03826641View on ClinicalTrials.gov

A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of HCP1801 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

85

Participants

Timeline

Start Date

February 1, 2019

Primary Completion Date

March 25, 2019

Study Completion Date

April 16, 2019

Conditions
Healthy
Interventions
DRUG

HCP1805

Dapagliflozin/Metformin (Xigduo XR) 10/1000mg

DRUG

HCP1801

Dapagliflozin/Metformin 10/1000mg

Trial Locations (1)

Unknown

Kyungpook National University Hospital, Daegu

Sponsors
All Listed Sponsors
lead

Hanmi Pharmaceutical Company Limited

INDUSTRY

NCT03826641 - A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of HCP1801 in Healthy Subjects | Biotech Hunter | Biotech Hunter